Cargando…

Multidrug-resistant Tuberculosis in Central Asia

Multidrug-resistant tuberculosis (MDR-TB) has emerged as a major threat to TB control, particularly in the former Soviet Union. To determine levels of drug resistance within a directly observed treatment strategy (DOTS) program supported by Médecins Sans Frontières in two regions in Uzbekistan and T...

Descripción completa

Detalles Bibliográficos
Autores principales: Cox, Helen Suzanne, Orozco, Juan Daniel, Male, Roy, Ruesch-Gerdes, Sabine, Falzon, Dennis, Small, Ian, Doshetov, Darebay, Kebede, Yared, Aziz, Mohammed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3323206/
https://www.ncbi.nlm.nih.gov/pubmed/15200821
http://dx.doi.org/10.3201/eid1005.030718
_version_ 1782229151605850112
author Cox, Helen Suzanne
Orozco, Juan Daniel
Male, Roy
Ruesch-Gerdes, Sabine
Falzon, Dennis
Small, Ian
Doshetov, Darebay
Kebede, Yared
Aziz, Mohammed
author_facet Cox, Helen Suzanne
Orozco, Juan Daniel
Male, Roy
Ruesch-Gerdes, Sabine
Falzon, Dennis
Small, Ian
Doshetov, Darebay
Kebede, Yared
Aziz, Mohammed
author_sort Cox, Helen Suzanne
collection PubMed
description Multidrug-resistant tuberculosis (MDR-TB) has emerged as a major threat to TB control, particularly in the former Soviet Union. To determine levels of drug resistance within a directly observed treatment strategy (DOTS) program supported by Médecins Sans Frontières in two regions in Uzbekistan and Turkmenistan, Central Asia, we conducted a cross-sectional survey of smear-positive TB patients in selected districts of Karakalpakstan (Uzbekistan) and Dashoguz (Turkmenistan). High levels of MDR-TB were found in both regions. In Karakalpakstan, 14 (13%) of 106 new patients were infected with MDR-TB; 43 (40%) of 107 previously treated patients were similarly infected. The proportions for Dashoguz were 4% (4/105 patients) and 18% (18/98 patients), respectively. Overall, 27% of patients with positive smear results whose infections were treated through the DOTS program in Karakalpakstan and 11% of similar patients in Dashoguz were infected with multidrug-resistant strains of TB on admission. These results show the need for concerted action by the international community to contain transmission and reduce the effects of MDR-TB.
format Online
Article
Text
id pubmed-3323206
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-33232062012-04-17 Multidrug-resistant Tuberculosis in Central Asia Cox, Helen Suzanne Orozco, Juan Daniel Male, Roy Ruesch-Gerdes, Sabine Falzon, Dennis Small, Ian Doshetov, Darebay Kebede, Yared Aziz, Mohammed Emerg Infect Dis Research Multidrug-resistant tuberculosis (MDR-TB) has emerged as a major threat to TB control, particularly in the former Soviet Union. To determine levels of drug resistance within a directly observed treatment strategy (DOTS) program supported by Médecins Sans Frontières in two regions in Uzbekistan and Turkmenistan, Central Asia, we conducted a cross-sectional survey of smear-positive TB patients in selected districts of Karakalpakstan (Uzbekistan) and Dashoguz (Turkmenistan). High levels of MDR-TB were found in both regions. In Karakalpakstan, 14 (13%) of 106 new patients were infected with MDR-TB; 43 (40%) of 107 previously treated patients were similarly infected. The proportions for Dashoguz were 4% (4/105 patients) and 18% (18/98 patients), respectively. Overall, 27% of patients with positive smear results whose infections were treated through the DOTS program in Karakalpakstan and 11% of similar patients in Dashoguz were infected with multidrug-resistant strains of TB on admission. These results show the need for concerted action by the international community to contain transmission and reduce the effects of MDR-TB. Centers for Disease Control and Prevention 2004-05 /pmc/articles/PMC3323206/ /pubmed/15200821 http://dx.doi.org/10.3201/eid1005.030718 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research
Cox, Helen Suzanne
Orozco, Juan Daniel
Male, Roy
Ruesch-Gerdes, Sabine
Falzon, Dennis
Small, Ian
Doshetov, Darebay
Kebede, Yared
Aziz, Mohammed
Multidrug-resistant Tuberculosis in Central Asia
title Multidrug-resistant Tuberculosis in Central Asia
title_full Multidrug-resistant Tuberculosis in Central Asia
title_fullStr Multidrug-resistant Tuberculosis in Central Asia
title_full_unstemmed Multidrug-resistant Tuberculosis in Central Asia
title_short Multidrug-resistant Tuberculosis in Central Asia
title_sort multidrug-resistant tuberculosis in central asia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3323206/
https://www.ncbi.nlm.nih.gov/pubmed/15200821
http://dx.doi.org/10.3201/eid1005.030718
work_keys_str_mv AT coxhelensuzanne multidrugresistanttuberculosisincentralasia
AT orozcojuandaniel multidrugresistanttuberculosisincentralasia
AT maleroy multidrugresistanttuberculosisincentralasia
AT rueschgerdessabine multidrugresistanttuberculosisincentralasia
AT falzondennis multidrugresistanttuberculosisincentralasia
AT smallian multidrugresistanttuberculosisincentralasia
AT doshetovdarebay multidrugresistanttuberculosisincentralasia
AT kebedeyared multidrugresistanttuberculosisincentralasia
AT azizmohammed multidrugresistanttuberculosisincentralasia